Stanford Cancer Institute
Stanford MEDICINE

Stanford Cancer Institute

Lymphoma

Version Date:
18 April 2019

Low Grade Lymphoma

- MATCH Screening
  - No mutation match
    - Grade 1-3a
      - Biopsiable Site
        - **LYMNHL0135** ❖ Intratumoral Injection of SD-101 in Combo w/ Ibrutinib & Local Radiation in Follicular Lymphoma
          PI: Levy
          Stanford
          1st Priority
        - **LYMNHL0144** ❖ SD-101 in Combo w/ BMS-986178 & Local Radiation in Low-Grade B-Cell Lymphomas
          PI: Levy
          Stanford
          2nd Priority
      - No Biopsiable Site
        - **LYMNHL0139** ❖ Phase IbII Hu5F9-G4 in Combo w/ Rituximab in Relapsed/ Refractory B-cell Non-Hodgkin's Lymphoma
          PI: Advani
          Forty Seven Inc.
  - If matches (a) mutation(s) in 1 ≤ treatment arms
    - **ECOG-ACRIN-EAY131** ❖ Molecular Analysis for Therapy Choice (MATCH)
      PI: Ford
      ECOG-ACRIN
- Non Treatment Studies
  - Systemic Treatment with Curative Intent
    - **VAR0174** Leveraging Mindsets to Improve Health & Wellbeing in Patients with Cancer
      PI: Crum
      Stanford

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- ❖ Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu